<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952198</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-403-102</org_study_id>
    <nct_id>NCT00952198</nct_id>
  </id_info>
  <brief_title>A Safety Study of ARRY-403 in Patients With Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of&#xD;
      investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin&#xD;
      therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be&#xD;
      enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of study drug on glycemic control as determined by an oral glucose tolerance test (OGTT).</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ARRY-403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-403, glucokinase activator; oral</intervention_name>
    <description>multiple dose, escalating</description>
    <arm_group_label>ARRY-403</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (females must be of non-childbearing potential), between the ages of 18&#xD;
             and 70 years, inclusive.&#xD;
&#xD;
          -  Diagnosis of Type 2 diabetes.&#xD;
&#xD;
          -  Fasted C-peptide value ≥ 0.8 ng/mL.&#xD;
&#xD;
          -  HbA1c ≥ 6.5% and ≤ 10.0% for monotherapy cohorts (study drug only) or HbA1c ≥ 7.5% and&#xD;
             ≤ 10.0% for combination cohorts (study drug and on a stable regimen of metformin&#xD;
             monotherapy that includes a morning dose for ≥ 8 weeks prior to first dose of study&#xD;
             drug).&#xD;
&#xD;
          -  BMI ≥ 25.0 kg/m2 and ≤ 40.0 kg/m2&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Recent history (i.e. less than 6 months) or concomitant/ongoing clinically significant&#xD;
             hematologic, renal, pulmonary, gastrointestinal, hepatic, psychiatric, neurologic,&#xD;
             dermatologic or allergic disease (including drug allergies that are clinically&#xD;
             significant and not remote, but excluding untreated, asymptomatic, seasonal allergies&#xD;
             at the time of dosing), or other conditions at the discretion of the investigator.&#xD;
&#xD;
          -  Significant cardiac disease, myocardial infarction within 6 months of study start,&#xD;
             unstable angina, congestive heart failure, known arrhythmias of ventricular etiology,&#xD;
             unexplained syncope or syncope/seizures related to arrhythmia.&#xD;
&#xD;
          -  History of gastric surgery, vagotomy, bowel resection or any surgical procedure that&#xD;
             might interfere with gastrointestinal motility, pH, or absorption.&#xD;
&#xD;
          -  A positive test for drugs or alcohol.&#xD;
&#xD;
          -  Active infectious diseases including hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus (HIV). Past history and inactive hepatitis B and C, as&#xD;
             confirmed by serological testing, are allowed.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Donation or loss of ≥ 550 mL of blood (including plasmapheresis) or receipt of a&#xD;
             transfusion of any blood product within 8 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

